Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters시리아 골든 햄스터에서 SARS-CoV-2 Omicron BA.1(B.1.1.529) 변종 접종 후 폐 병변Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] animals B.1.1.529 B.1.617.2 characterized Clinical signs COVID-19 disease decrease Delta Disease progression disease severity evaluate Evidence evidence of golden hamster hamster hamsters histopathological Human Immune escape Immunity Infection inoculated intrinsic Kinetics lesion Mutation omicron Omicron BA.1 pathogenicity pathological changes pathology Pneumonia pre-existing immunity progression pulmonary re-challenge. reduced SARS-CoV-2 SARS-CoV-2 variant Syrian golden hamster the SARS-CoV-2 vaccination variant viral genome viral shedding viral spread virus [DOI] 10.1080/22221751.2022.2095932 PMC 바로가기 [Article Type] Article
From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?우한-Hu-1 변종에서 XD 및 XE 변종까지: SARS-CoV-2 스파이크 단백질을 표적으로 하는 것이 여전히 COVID-19에 대한 약학적으로 적절한 옵션입니까?Article Published on 2022-12-012022-09-11 Journal: Journal of Enzyme Inhibition and Medicinal Chemist [Category] COVID19(2023년), SARS, 변종, [키워드] contributing to COVID-19 COVID-19 pandemic death Efficacy feature glycoprotein hospitalisations infections milestone MPro Mutation mutations outbreak pandemic Paxlovid Protein reported SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 variant spike Spike protein Surface glycoprotein the SARS-CoV-2 the SARS-CoV-2 genome the Spike Treatment Vaccines variant viral surface Wuhan-Hu-1 XD variant XE variant. [DOI] 10.1080/14756366.2022.2081847 PMC 바로가기 [Article Type] Article
Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variantsArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition adenoviral vector Adenovirus adenovirus type 5 vector vaccine Anti-RBD IgG booster COVID-19 COVID-19 vaccine D614G demonstrated dose effective Efficacy IgA immunization Inactivated vaccine Inactivated Vaccines Inhaled lack mucosal Neutralization assay Neutralizing neutralizing antibody omicron Omicron variant BA.5 pandemic plasma Protective RBD SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 vaccines SARS-CoV-2 variant subunit titre Vaccination strategies vaccination strategies. Vaccination strategy Vaccine variant virus widespread [DOI] 10.1080/22221751.2022.2132881 PMC 바로가기
The Drosophila melanogaster ACE2 ortholog genes are differently expressed in obesity/diabetes and aging models: Implications for COVID-19 pathologyArticle Published on 2022-12-012022-11-15 Journal: Biochimica et biophysica acta. Molecular basis of [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 ACE2 ortholog ACE2 orthologs ACE2 receptor Acer age analyzed Ance animal model approach bind binding affinity complement coronavirus disease COVID-19 COVID-19 pathology COVID-19 severity death dependent on diabetes disorders Drosophila melanogaster Effect elderly ENhance expressed Factors glycoprotein host cells humans increase individual interact Interaction molecular molecular docking mRNA expression obesity ortholog predicted Protein regions regulated Research responsible risk factor Risk factors. robust SARS-CoV-2 SARS-CoV-2 variant shown spike spike-ACE2 susceptible the Spike translational Transmissibility virus [DOI] 10.1016/j.bbadis.2022.166551 PMC 바로가기
Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens4가지 프라이밍-부스팅 요법으로 유발된 SARS-CoV-2 변이체에 대한 중화 항체의 일대일 비교Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] comparison elicited neutralizing antibody regimen SARS-CoV-2 variant [DOI] 10.1080/22221751.2022.2095931 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysisArticle Published on 2022-12-012022-11-16 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Analysis Beta booster vaccination caused Clinical outcome collected Coverage COVID-19 vaccine COVID-19 vaccine effectiveness declined Delta driven by Effectiveness eligibility criteria evaluated Evolution Gamma Hospitalization Infection literature review Meta-analysis meta-regression moderate omicron protective vaccine provided public health public health measures Real-world study SARS-CoV-2 SARS-CoV-2 variant searched severe disease supported vaccination Vaccine variant variants of concern variants of concern. virus VoC VOCs [DOI] 10.1080/22221751.2022.2122582 PMC 바로가기
Rapid detection of SARS-CoV-2 variants of concern by single nucleotide polymorphism genotyping using TaqMan assaysArticle Published on 2022-12-012022-11-15 Journal: Diagnostic microbiology and infectious disease [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] 95% CI Accuracy acute respiratory syndrome approach B.1.1.7 B.1.526 clinical setting Concordance coronavirus coronavirus disease 19 Coronavirus disease 19 (COVID-19) E484K evaluated genotyping mutations N501Y nasopharyngeal Negative predictive value New York City nonsynonymous patient population polymorphism positive positive sample predicted ranged Rapid Real-time reverse-transcription PCR residual RT-qPCR SARS-CoV-2 SARS-CoV-2 testing SARS-CoV-2 variant sensitivity Sequencing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly lower single nucleotide specificity Spike protein submitted subset TaqMan TaqMan assay Thermofisher variant variants variants of concern. were used WGS whole genome [DOI] 10.1016/j.diagmicrobio.2022.115789 PMC 바로가기
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccinesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine antibody B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine booster center contributed Control COVID-19 Delta dose Effectiveness elicited faster FIVE Gamma immunization moderate mRNA-1273 mRNA-based vaccine Mutation Neutralizing Neutralizing antibodies neutralizing antibody omicron P.1 postvaccination prevention Protein pseudovirus receiving recipient recommendation robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant subject Support vaccination Vaccine vaccine efficacy variants of concern variants of concern (VOCs). VoC VOCs wild type [DOI] 10.1002/jmv.28032 PMC 바로가기